Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin

Alimentary Pharmacology and Therapeutics

Volumn 45, Issue 11, 2017, Pages 1427-1432

  Pillai, A A ^a   Maheshwari, R ^b   Vora, R ^b   Norvell, J P ^b   Ford, R ^b   Parekh, S ^b   Cheng, N ^b   Patel, A ^b   Young, N ^b   Spivey, J R ^b   Mgbemena, O ^b   Wedd, J P ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CALCINEURIN INHIBITOR; LEDIPASVIR PLUS SOFOSBUVIR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLATE MOFETIL; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR; SOFOSBUVIR;

ADULT; ARTICLE; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; GRAFT RECIPIENT; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIRUS LOAD; AGED; COMBINATION DRUG THERAPY; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; STATISTICAL MODEL; SUSTAINED VIROLOGIC RESPONSE;

AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 85017644625     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.14059     Document Type: Article

References (21)

1. Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32(4 Pt 1): 852–858.
2. Kim WR, Smith JM, Skeans MA, et al. OPTN/SRTR 2012 annual data report: liver. Am J Transplant 2014; 14(suppl 1): 69–96.
3. Wright TL, Donegan E, Hsu HH, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103: 317–322.
4. Gane EJ, Agarwal K. Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: “a flood of opportunity”. Am J Transplant 2014; 14: 994–1002.
5. Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8: 679–687.
6. Gordon FD, Kwo P, Ghalib R, et al. Peginterferon-alpha-2b and ribavirin for hepatitis C recurrence postorthotopic liver transplantation. J Clin Gastroenterol 2012; 46: 700–708.
7. Lawitz EJ, Gruener D, Hill JM, et al. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 2012; 57: 24–31.
8. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889–1898.
9. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879–1888.
10. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149: 649–659.
11. Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016; 16: 685–697.
12. Njei B, McCarty TR, Fortune BE, Lim JK. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis. Aliment Pharmacol Ther 2016; 44: 1090–1101.
13. Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Real world effectiveness of ledipasvir/sofosbuvir in 4365 treatment-naive genotype 1 hepatitis C infected patients. Hepatology 2016; 64: 405–14.
14. Stravitz RT, Kramer AH, Davern T, et al. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med 2007; 35: 2498–2508.
15. Butt AA, Yan P, Marks K, Shaikh OS, Sherman KE, Team ES. Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVES. Aliment Pharmacol Ther 2016; 44: 728–737.
16. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965.
17. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–982.
18. Younossi ZM, Stepanova M, Nader F, Lam B, Hunt S. The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life. Aliment Pharmacol Ther 2015; 42: 286–295.
19. Kwok RM, Ahn J, Schiano TD, et al. Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients. Liver Transpl 2016; 22: 1536–1543.
20. Shoreibah MG, Jones D, Baggett S, McGuire BM, Massoud O. Outcomes of ribavirin free regimens for treatment of recurrent hepatitis C (genotype1) infection post liver transplant. The AASLD Liver Meeting; November 13-17, 2015; San Francisco, CA.
21. Hassett MS, et al. Eflicacy and Tolerability of a 12 week Course of Sofosbuvir-basad HCV Antiviral Therapy without Ribavirin for Treatment of Recurrent HCV Genotype 1 Infection after Liver Transplantation The AASLD Liver Meeting; November 13-17, 2015; San Francisco, CA.